Published in PLoS One on February 06, 2015
The Unique Molecular and Cellular Microenvironment of Ovarian Cancer. Front Oncol (2017) 0.81
Significance of Interleukin-6 in Papillary Thyroid Carcinoma. J Thyroid Res (2016) 0.75
Interferon signaling in ascites-associated macrophages is linked to a favorable clinical outcome in a subgroup of ovarian carcinoma patients. BMC Genomics (2017) 0.75
Malignant ascites enhances migratory and invasive properties of ovarian cancer cells with membrane bound IL-6R in vitro. Oncotarget (2016) 0.75
Epithelial-mesenchymal transition and inflammation at the site of the primary tumor. Semin Cancer Biol (2017) 0.75
PRKCI promotes immune suppression in ovarian cancer. Genes Dev (2017) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Microenvironmental regulation of metastasis. Nat Rev Cancer (2008) 15.76
Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer (2004) 14.55
Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood (2005) 4.29
Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis (2007) 4.05
Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med (2012) 3.54
Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res (2011) 2.85
Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev (2012) 2.82
Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia. J Clin Oncol (2012) 2.24
Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol (2005) 1.92
Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res (2006) 1.84
Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. Br J Cancer (2008) 1.75
Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors. Pathol Int (2009) 1.68
Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients. Nat Protoc (2006) 1.56
Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice. Cancer Res (2007) 1.50
Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer (1994) 1.50
Inflammation and ovarian cancer. Cytokine (2012) 1.49
Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer (1995) 1.44
Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Cancer Res (1990) 1.42
Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment. Cancer Res (2013) 1.28
Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse. Int J Cancer (2013) 1.27
Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma. Clin Cancer Res (2009) 1.24
Targeted anti-vascular therapies for ovarian cancer: current evidence. Br J Cancer (2013) 1.21
A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res (2009) 1.20
Scavenger receptor-A-targeted leukocyte depletion inhibits peritoneal ovarian tumor progression. Cancer Res (2007) 1.18
Interleukin-6 signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells. Cytokine (2012) 1.11
Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelial cancer. Cancer (1993) 1.08
Elevated and secreted phospholipase A₂ activities as new potential therapeutic targets in human epithelial ovarian cancer. FASEB J (2012) 0.94
Interleukin-6/interleukin-6 receptor pathway as a new therapy target in epithelial ovarian cancer. Curr Pharm Des (2012) 0.94
IL-1 and IL-6 release by tumor-associated macrophages from human ovarian carcinoma. Int J Cancer (1989) 0.89
Humanised antihuman IL-6R antibody with interferon inhibits renal cell carcinoma cell growth in vitro and in vivo through suppressed SOCS3 expression. Eur J Cancer (2012) 0.85
Expression of soluble interleukin-6 receptor in malignant ovarian tissue. Am J Obstet Gynecol (2010) 0.83
The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma. Oncotarget (2015) 0.96
Interstitial pregnancy resulting in a viable infant coexistent with massive perivillous fibrin deposition: a case report and literature review. AJP Rep (2014) 0.84
Abnormal pressure-wave reflection in pregnant women with chronic hypertension: association with maternal and fetal outcomes. Hypertens Res (2014) 0.83
Characterization of subpopulation lacking both B-cell and plasma cell markers in Waldenstrom macroglobulinemia cell line. Lab Invest (2013) 0.79
Exosomes Promote Ovarian Cancer Cell Invasion through Transfer of CD44 to Peritoneal Mesothelial Cells. Mol Cancer Res (2016) 0.79
Aldosterone stimulates the proliferation of uterine leiomyoma cells. Gynecol Endocrinol (2010) 0.79
IKKβ Regulates VEGF Expression and Is a Potential Therapeutic Target for Ovarian Cancer as an Antiangiogenic Treatment. Mol Cancer Ther (2015) 0.78
Synchronous bilateral tonsillar carcinomas associated with human papillomavirus. Auris Nasus Larynx (2013) 0.77
Drug Repositioning for Preeclampsia Therapeutics by In Vitro Screening: Phosphodiesterase-5 Inhibitor Vardenafil Restores Endothelial Dysfunction via Induction of Placental Growth Factor. Reprod Sci (2015) 0.77
Feto-maternal outcomes of pregnancy complicated by ovarian malignant germ cell tumor: a systematic review of literature. Eur J Obstet Gynecol Reprod Biol (2014) 0.76
Wilms' tumor gene WT1 promotes homologous recombination-mediated DNA damage repair. Mol Carcinog (2014) 0.76
Pure Primary Ovarian Squamous Cell Carcinoma Perforating the Rectum. Case Rep Obstet Gynecol (2017) 0.75
Immune tolerance induction using fetal directed placental injection in rodent models: a murine model. PLoS One (2015) 0.75
Thrombocytopenia associated with Mycoplasma pneumonia during pregnancy: case presentation and approach for differential diagnosis. J Obstet Gynaecol Res (2015) 0.75
Investigation of the clinicopathological features of squamous cell carcinoma of the vulva: a retrospective survey of the Tohoku Gynecologic Cancer Unit. Int J Clin Oncol (2015) 0.75
'Smartscopy' as an alternative device for cervical cancer screening: a pilot study. BMJ Innov (2017) 0.75
Effects of minodronate in postmenopausal women with osteoporosis who received prior treatment with raloxifene. Int J Womens Health (2017) 0.75
Intense fluorodeoxyglucose uptake by a benign sclerosing stromal tumor of the ovary. Taiwan J Obstet Gynecol (2016) 0.75
Salvage high-dose-rate brachytherapy for isolated vaginal recurrence of endometrial cancer. Brachytherapy (2016) 0.75
Extraperitoneal Radical Trachelectomy With Pelvic Lymphadenectomy: A Novel Fertility-Preserving Option for Early Stage Cervical Cancer Patients. Int J Gynecol Cancer (2017) 0.75
Hepatic portal venous gas: a rare complication of malignant bowel obstruction during the administration of octreotide. J Pain Symptom Manage (2013) 0.75
Incidence of Gastric Adenocarcinoma among Lesions Diagnosed as Low-grade Adenoma/Dysplasia on Endoscopic Biopsy: A Multi-center, Prospective, Observational Study. Dig Endosc (2017) 0.75
First two cases of primary carcinoma of the vagina successfully treated with concurrent weekly carboplatin plus paclitaxel, external beam radiotherapy and high-dose-rate interstitial brachytherapy: a case report and published work review. J Obstet Gynaecol Res (2014) 0.75